CMS grants permanent J-code J9248 for Delcath's HEPZATO, effective April 1, 2024

DELCATH SYSTEMS, INC.

CMS established permanent product-specific J-code (J9248) for HEPZATO (melphalan/Hepatic Delivery System).
J-code becomes effective April 1, 2024, enabling streamlined Medicare Part B billing for HEPZATO.
CMS noted existing IV melphalan (0.25 mg/kg) is not substitutable for HEPZATO (3.0 mg/kg intraarterial).
HEPZATO is liver-directed treatment for adult patients with metastatic uveal melanoma with hepatic metastases.
CEO Gerard Michel says J-code will facilitate patient access and efficient reimbursement for HEPZATO KIT.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.